This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study of Cardiac Safety in Patients With HER2 Positive Early Breast Cancer Treated With Herceptin

This study has been completed.
Information provided by (Responsible Party):
Hoffmann-La Roche Identifier:
First received: June 28, 2010
Last updated: August 10, 2017
Last verified: August 2017
This is a single cohort observational safety study. All patients will be treated and monitored according to the local clinical practice. No additional procedures/patient visits in comparison with the usual clinical practice are planned for the study. Data will be collected from centre's medical records for up to 5 years or death.

Condition Intervention
Breast Cancer Drug: trastuzumab [Herceptin]

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: An Observational Study of Cardiac Events in Patients With HER2 Positive Early Breast Cancer Treated With Herceptin

Resource links provided by NLM:

Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Incidence of symptomatic congestive heart failure\n(CHF) using New York Heart Association class II, III and IV, and cardiac death [ Time Frame: On treatment and up to 5 years follow-up ]

Secondary Outcome Measures:
  • Time to onset and the time to recovery of symptomatic congestive heart failure [ Time Frame: On treatment and up to 5 years follow-up ]
  • Incidence of asymptomatic cardiac failure and other significant cardiac conditions [ Time Frame: On treatment and up to 5 years follow-up ]

Enrollment: 3942
Actual Study Start Date: August 30, 2007
Study Completion Date: May 27, 2016
Primary Completion Date: March 27, 2016 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Cohort Drug: trastuzumab [Herceptin]
There is no planned investigational product or a treatment regimen prescribed by this protocol. Decision about a treatment regimen will be made according to the local practice and in the best interest of individual patients.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
HER2-positive Breast Cancer

Inclusion Criteria:

  • All patients who are considered candidates to receive Herceptin for this indication

Exclusion Criteria:

  • Patients for whom Herceptin is contraindicated
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01152606

  Show 205 Study Locations
Sponsors and Collaborators
Hoffmann-La Roche
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

Responsible Party: Hoffmann-La Roche Identifier: NCT01152606     History of Changes
Other Study ID Numbers: BO20652
Study First Received: June 28, 2010
Last Updated: August 10, 2017

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antineoplastic Agents processed this record on September 21, 2017